FMS dividend history

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1 billion. The first tranche, amounting up to EUR 600 million, was initiated today and is expected to be completed by December 15, 2026. The share buyback program is part of the Company's capital allocation framework, complementing dividends and reflecting FME's commitment to disciplined, value-fo

Total volume of the share buyback is around EUR 1 billion over 12 monthsShare buyback expected to begin in the near futureBAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, intends to execute a new share buyback program with a total volume of around EUR 1 billion. The program shall be executed in tranches over a period of 12 months from its start. The share buyback program is based on the authorization to purchase and use treasury shares granted by the Company

Shareholders approve proposed dividend of EUR 1.49 per shareFME Reignite strategy launched in 2025 successfully drives the next phase of value creation5008X CAREsystem introduced in U.S. clinics; full U.S. commercial launch underway in 2026EUR 1 billion share buyback program successfully completed, and a new authorization granted to support the Company's capital allocation framework which includes share buyback programsBAD HOMBURG, Germany, May 21, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in profitability. Over the past three y

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol

Today's Annual General Meeting was the first one following the change in legal form completed in November 2023Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous yearNew compensation system for Management Board approvedAmbitious growth targets for 2024 confirmedBAD HOMBURG, Germany, May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.